Jessica L Geiger1, Nofisat Ismaila2, Beth Beadle3, Jimmy J Caudell4, Nicole Chau5, Daniel Deschler6, Christine Glastonbury7, Marnie Kaufman8, Eric Lamarre1, Harold Y Lau9, Lisa Licitra10,11, Michael G Moore12, Cristina Rodriguez13, Anna Roshal14, Raja Seethala15, Paul Swiecicki16, Patrick Ha7. 1. Cleveland Clinic, Cleveland, OH. 2. American Society of Clinical Oncology, Alexandria, VA. 3. Stanford University, Stanford, CA. 4. Moffitt Cancer Center, Tampa, FL. 5. BC Cancer, Vancouver, BC, Canada. 6. Massachusetts Eye and Ear Infirmary, Boston, MA. 7. University of California San Francisco, San Francisco, CA. 8. Adenoid Cystic Carcinoma Research Foundation, Needham, MA. 9. University of Calgary, Calgary, AB, Canada. 10. Istituto Nazionale Tumori, Milan, Italy. 11. University of Milan, Milan, Italy. 12. Indiana University School of Medicine, Indianapolis, IN. 13. University of Washington, Seattle, WA. 14. Indiana University Health, Indianapolis, IN. 15. University of Pittsburgh, Pittsburgh, PA. 16. University of Michigan, Ann Arbor, MI.
Abstract
PURPOSE: To provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy. METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, neuroradiology, pathology, and patient advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2020. Outcomes of interest included survival, diagnostic accuracy, disease recurrence, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 293 relevant studies to inform the evidence base for this guideline. Six main clinical questions were addressed, which included subquestions on preoperative evaluations, surgical diagnostic and therapeutic procedures, appropriate radiotherapy techniques, the role of systemic therapy, and follow-up evaluations. RECOMMENDATIONS: When possible, evidence-based recommendations were developed to address the diagnosis and appropriate preoperative evaluations for patients with a salivary gland malignancy, therapeutic procedures, and appropriate treatment options in various salivary gland histologies.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
PURPOSE: To provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy. METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, neuroradiology, pathology, and patient advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2020. Outcomes of interest included survival, diagnostic accuracy, disease recurrence, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 293 relevant studies to inform the evidence base for this guideline. Six main clinical questions were addressed, which included subquestions on preoperative evaluations, surgical diagnostic and therapeutic procedures, appropriate radiotherapy techniques, the role of systemic therapy, and follow-up evaluations. RECOMMENDATIONS: When possible, evidence-based recommendations were developed to address the diagnosis and appropriate preoperative evaluations for patients with a salivary gland malignancy, therapeutic procedures, and appropriate treatment options in various salivary gland histologies.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
Authors: Sarah Atallah; Morgane Marc; Antoine Schernberg; Florence Huguet; Isabelle Wagner; Antti Mäkitie; Bertrand Baujat Journal: Cancer Manag Res Date: 2022-06-04 Impact factor: 3.602
Authors: Rebecca R Pharaon; Thomas Gernon; Sue Chang; Nayana Vora; Victoria M Villaflor; Diana Bell; Michelle Afkhami; Arya Amini; Sagus Sampath; Robert Kang; Ellie G Maghami; Erminia Massarelli Journal: Cold Spring Harb Mol Case Stud Date: 2022-04-28
Authors: Maike José Maria Uijen; Jetty Anne Mina Weijers; Chantal Maria Leonarda Driessen; Carla Marie Louise van Herpen; James Nagarajah Journal: Clin Nucl Med Date: 2022-02-01 Impact factor: 7.794